Author of

• 20155

  +

  P1.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation (ID 692)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Epidemiology/Primary Prevention/Tobacco Control and Cessation
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22657

    +

    P1.06-013 - Latent Tuberculosis in Newly Diagnosed Lung Cancer Patients. An Spanish Prospective Study (ID 9599)

    09:30 - 09:30  |  Author(s): I. Burgueño Lorenzo
    • Abstract

    Background:
    Lung cancer and tuberculosis (TB) share common risk factors and are associated with high morbidity and mortality. Coexistence of lung cancer and TB were reported in previous studies, with uncertain pathogenesis. The association between lung cancer and latent TB infection (LTBI) remains to be explored. In Spain the prevalence is higher compared to other European countries and there are a high emigration rates. The key objetive is to place value on the need to detect LTBI for assesment for prophylaxis in patients at risk of reactivation due to cancer and cancer treatments.
    
    Method:
    Newly diagnosed , treatment-naïve advanced lung cancer patients from October-December 2015 and from October-December 2016 were prospectively enrolled .The presence of LTBI was determined by QuantiFERON-TB Gold In-Tube (QFT-GIT). Demographic characteristics and cancer-related factors associated with LTBI were investigated.
    
    Result:
    A total of 67 lung cancer patients were enrolled. The patients demographics were: median age 64 years, 10 (15%) female and 58 (85%) male. Adenocarcinoma 50% (n=34) , 23% (n=16) squamous-cell carcinoma and small cell lung cancer 26% ( n= 18) The stage was IV in 71%(n=53) and III in 29% (n=20) These patients come from urban area in 16% of cases and rural areas in the 83% and the 82% (n=56) had history of smoking. The 79,4% % ( n= 54) of patients received chemotherapy and 16% ( n= 11) inunotherapy with Nivolumab. Among these patients including 23 % (n=16) LTBI,65% (n=44) non-LTBI, and 12% (n=8 ) QFT-GIT results-indeterminate cases. Out of these LTBI patients received Isoniazid chemoprophylaxis only 60% because of poor performance status. Adenocarcinoma had higher proportion of LTBI 64% vs 18 % for epidermoid and 18% for oat-cell At the time of database lock, the median of overall survival was only 6 months.
    
    Conclusion:
    Nearly a quarter of newly diagnosed advanced lung cancer patients in Toledo ( Spain) have LTBI. There is a lack of widely acceptable and established standards for screening for latent TB in patients undergoing treatment for active solid-organ malignancy. Perhaps is recommended screening all patients born in countries with endemic TB before beginning radiotherapy or chemotherapy to avoid TB reactivation.